Supporting Research

Progesterone, conflicting research regarding Cancer, Covid-19 and Estrogen Cross-Talk Coming into Better Focus 2021 American Journal of Cancer Research Paper

This review tries to describe the physiological functions of progesterone and its receptors, genomic and non-genomic signaling, splice variants, and a different aspect of progesterone signaling. Furthermore, we seek to address or attempt to discuss the following pertinent questions on steroid hormone signaling; How does progesterone influence breast cancer progression? How does it change the molecular pathways in breast cancer with different receptor statuses, the specific role of each isoform, and how does the ER/and PR ratio affect progesterone signaling?

The truth about the WHI:


Here's a paper that shows physiologic estrogen has benefits.

This wonderful complete summary by Dr. Nylon K Eccles details why natural transdermal progesterone is needed in hormone replacement and why progesterone is needed when a woman does not have a uterus!! Bravo!

This is the editorial of Dr. Felice Gersh's Menopause and Hormone Replacement Therapy in the 21st Century article published by the BMJ.

Felice Gersh is the principal investigator for the Women’s Hormone Network research project comparing physiologic restoration with standard estradiol patch and cyclical oral progesterone. She is the first author for this paper, “Postmenopausal hormone therapy for cardiovascular health: the evolving data” which we consider a landmark article for prescribing hormone replacement therapy for cardiovascular health.


Felice Gersh MD, one of our esteemed faculty members, has published this article on Menopause status and Covid 19 by Oxford University Press for the Infectious Diseases Society of America.


Research shows that bioidentical hormones are more efficacious than their synthetic and animal derived counterparts and remain the preferred method of HRT.

The following Abstract discusses BBHRT (Biomimetic Bioidentical Hormone Replacement Therapy) for breast cancer patients, and their effect on quality of life.

BBHRT History

First developed by T. S. Wiley as the Wiley Protocol, Biomimetic Bio-identical HRT (BBHRT) has been in the public domain for over 17 years. Physiologic Restoration has its origins in BBHRT. The abstract refers to the use of BBHRT in Oncologist Dr. Julie Taguchi’s observational study of oncology and the subjective improvement of menopausal symptoms.

WHN Board Member, Dr. Julie Taguchi is currently the Principal Investigator of the new and critically important BHOT (Bioidentical Hormones on Trial) study for WHN. We will keep you posted on our progress with this key study, and will publish the results.

Bone density improvement can be significant for women on Rhythmic Hormone Restoration.

This is a patient screening that shows after 7 years on the protocol, ages 52-59, bone mineral density (BMD) in the hip increased from 0.998 g/cm2 (normal) to 1.109 g/cm2 in 7 years or a total 12.3% increase in 7 years.

BMD in the spine also increased 5.4% over 7 years, but started out as normal bone.

Note that BMD is different in different bones and that gain or loss of bone occurs at different rates as well.

Hologic 1
Hologic 2

The goal of WHN is to expand the Standard of Care by promoting, advocating, and advancing women's wellbeing and longevity through clinical research and education about the benefits of Physiologic Restoration to reduce the symptoms of hormone imbalance, chronic disease and degenerative decline.
WHN is a registered 501(c)3 not-for-profit corporation